Immunocore is the world's leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases. Its ImmTAC technology enables circulating T cells to selectively identify and kill diseased cells with ultra-high specificity and potency and reduced toxicity.

 

Background

  • Lead candidate in Phase IIa studies in metastatic melanoma
  • Europe’s largest ever private financing round in biotech with a raise of $320 million in July 2015
  • Bill & Melinda Gates Foundation investment of $40 million for collaboration in infectious diseases

$320m

Europe’s largest ever private financing round in biotech

 

Our strategy

  • Detailed review and overhaul of all corporate materials, including key messages
  • Extensive programme of media introductions in the weeks before the fundraise announcement, ensuring that key journalists knew the company well
  • Placement of fundraise story under embargo, yielding worldwide coverage including Financial Times, WSJ, New York Times, newswires and international trade press.

 

Outcome

  • Extensive coverage across all international leading media, business and trade press
  • Momentum continued with follow-up coverage in the Financial Times (Lombard), Washington Post, The Sunday Times (featured CEO interview) and New York Times